Novavax Inc (NVAX): Cost of Revenue
$73.04M
Year ended 2025-12-31
$88.54M
Trailing 12 months to 2026-06-30
-56.7%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $73.04M | -64.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $202.74M | -41.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $343.77M | -61.9% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $902.64M | n/a | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2023-02-28, From 2020-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $352.01M | -2.2% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $790.50M | -21.8% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $83.70M | +9.8% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $217.41M | +5.1% |
Compare NVAX, TECH, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗